Topic Archives: hypertension

Comments

  • Avatar

    On getting older (now 65), started experiencing negative health effects (overweight, hypertension, leaky gut), and so st...

  • JohnM

    $BLPH long (ouch), rumrunner, thanks for your thoughts. When you say "INO pulse could not sustain patients beyond very s...

  • Avatar

    Another company in a very similar situation (starting Phase III trials) is Reservalogix, RVX.TO, RVXCF, with a C$400M ma...

  • Gr8Full!

    $MOLN > MEDIA RELEASE http://e1.marco.ch/publish/konsulenten/20_8155/20180615_EHA_Stockholm.pdf Press Release (PDF...

  • Gr8Full!

    $BLPH wow > 8K filed.... http://investors.bellerophon.com/phoenix.zhtml?c=253899&p=irol-SECText&TEXT=aHR0cDovL2FwaS50ZW...

  • Avatar

    Just thinking, if this is a topical gel, does it need to be wiped clean prior to coitus as there may be the unintended s...

  • Avatar

    Sharon et al - My wife works with the young man's mother and this is a better description of what has happened. He...

  • Avatar

    $BLPH “Bellerophon Therapeutics Announces Enrollment Exceeds 100 Patients In Phase 3 INOvation-1 Study Evaluating I...

  • Avatar

    I apologize for being remiss in answering in a timely fashion. I'm allegedly retired, which I've come to learn is more ...

  • Avatar

    $BLPH long fp - Bellerophon Therapeutics Announces Enrollment Exceeds 100 Patients in Phase 3 INOvation-1 Study Evaluati...

  • Avatar

    $APTO ow big time So glad you’re back Doc. I suspected you would be in time for NobleCon. After $APTO retreated a ...

  • Avatar

    Good afternoon - This is a plea for some help. My wife and I have a friend whose young son, 15, went to scout camp and...

  • Avatar

    $BLPH nervous long H.C. Wainwright initiates coverage on Bellerophon Therapeutics (NASDAQ: BLPH) with a Buy rating and ...

  • Avatar

    Comment should read " hypertension OR women"....

  • Avatar

    Well written and accurate. This review should be required reading for ALL physicians treating hypertension of women who...

  • Avatar

    $ EIGR NP Eiger BioPharmaceuticals announces that the Phase 2 LIBERTY study in pulmonary arterial hypertension did n...

  • SoGiAm

    $BLPH ow - Title: Bellerophon Announces First Patient Enrolled in Phase 2b Study Evaluating INOpulse® for Treatment of...

  • SoGiAm

    #NEW http://e.endpointsnews.com/t/ViewEmail/t/4D8DE52AB226DD80/2F80028A944F69C925D77A725F39070E Sanofi’s belated a...

  • Avatar

    $BLPH LONG Bellerophon Therapeutics reports Q3 results (1.35) Co reports Q3 EPS of ($0.22) vs ($0.22) single a...

  • Avatar

    $CWBR $Mitochondria-based therapy $DCA New research report on mitochondria based therapy to treat PAH and cardiov...

  • Avatar

    hi Doc your concerns about fenfluramine $ZGNX were there "However, fenfluramine was withdrawn from global markets in 1...

  • Avatar

    $XLRN np Acceleron gains rights to fund, develop, and lead global commercialization of sotatercept in pulmonary arteria...

  • Avatar

    It's a coin flip, 50% of the time its under the ocular hypertension threshhold therefor not a good indicator for glucoma...

  • Avatar

    Thanks, Cleveland. Your post really helps me place the low MC in perspective. I thought my post was lost and placed anot...

  • Avatar

    $blph long Blph is a strange one to me..as far as trading goes. I don't worry too much about the up's and down's but th...

  • Avatar

    Long $BLPH Doc, one quick question: The Praxair ANDA was for delivery of NO to treat pulmonary hypertension. ...

  • Avatar

    Blph Doc/Helen, PAH (Pulmonary Arterial Hypertension) is Group 1 Pulmonary Hypertension which is essentially high press...

  • Avatar

    Bellerophon Announces Positive Top Line Phase 2 Data of INOpulse® for Treatment of Pulmonary Hypertension Associated wi...

  • Avatar

    $BLPH Doc, I would be very interested in learning whether BLPH has plans, however remote, to trial INOpulse in PAH pa...

  • Avatar

    $ESPR, $PIRS https://www.news-medical.net/news/20170816/Scientists-reveal-engineered-fusion-protein-that-could-recove...

  • Avatar

    $ Meth $Addiction $Stroke "Methamphetamine Use Tied to Heightened Hemorrhagic Stroke Risk" Medscape, August 25, 201...

  • Avatar

    The most common types of cardiovascular disease include hypertension, ischemic heart disease, cerebrovascular disease (s...

  • Avatar

    $BLPH A nice, lucid article published on a professional website, with key information about Bellerophon's innovative ...

  • SoGiAm

    $BLPH long – Join our KOL Webcast on Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD) Wednesd...

  • SoGiAm

    $BLPH long - Join our KOL Webcast on Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD) Wednesday...

  • Avatar

    $BLPH long 10:52 EDT BLPH theflyonthewall.com: Bellerophon to host a Key Opinion Leader Luncheon Key Opinion Le...

  • Dr. KSS MD PhD

    $GILD speculated to be eyeing United Therapeutics ($UTH), which markets several pulmonary hypertension drugs, for takeov...

  • Avatar

    $BLPH full position Yes, I saw that. At the end of the announcement, they talk about a KOL meeting on Aug. 9th. K...

  • Avatar

    $BLPH Bellerophon Announces FDA Agreement on Phase 2b Study Design for INOpulse® in Pulmonary Hypertension Associate...

  • Avatar

    $BLPH Marsupi - I am guessing you are looking at the July 31 date on the Gummie Google calendar for data on Ph 2 prog...

  • achandra13

    $BLPH INOpulse delivery device Pulmonary Hypertension associated with COPD (PH-COPD) Ph2 data is due by the end of this ...

  • Avatar

    To be fair, I should mention that no matter what, voclosporin will always have a better side effect profile than cyclosp...

  • Avatar

    $AUPH long Hi jocn16. Not enough data published to form an opinion on why the P3 trial failed to reach it's prima...

  • Dr. KSS MD PhD

    I don't personally, but I've considered it many times. In my view, the disease is insulin resistance, and diabetes is it...

  • Avatar

    $ARNA: I think ARENA has two shots that look reasonable.. the PAH (Pulmonary Arterial Hypertension) side first cab off t...

  • Avatar

    Yes $BLPH Corp website confirms they are planning a mid-2017 release of the Ino-Pulse data for Pulmonary Hypertension as...

  • Avatar

    $BLPH They should be releasing Phase 2 results for NO in COPD hopefully within next few weeks. I lifted this from SA...

  • JohnM

    7/24/15 Dr. KSS MD PhD Fundamentally, Kenny, your objection is the correct one. Most of the vitamin D literature is pu...

  • Avatar

    Q4 2017 Catalysts: Achaogan $AKAO (fp) Plazomycin NDA "2H'17" Portola $PTLA (fp) Possible launch of Andexanet 4Q 201...

  • Avatar

    Several July '17 catalysts coming: Windtree $WINT (sp) Phase 2 results due Recro Pharma $REPH (mp) NDA for IV Meloxica...

  • Dr. KSS MD PhD

    Not any, really. They aim to treat proopiomelanocortin deficiency states which few MD's ever see during a career. Even i...

  • Dr. KSS MD PhD

    Thanks paul. I am predicting a positive read. I feel the supporting basic science is good and marches in tune to the cli...

  • Avatar

    $No ticker Life expectancy varies from place to place in the US from as much as 86 years to as few as 66. What correl...

  • Avatar

    $BLPH Jabber, I totally forgot about the SPA for the Phase 3. Here is from company's press release March 2017: The ...

  • Dr. KSS MD PhD

    Agree.....media have whipped anything pertaining to antimicrobials into a frenzy, and few who write get what is clinical...

  • Avatar

    $PTLA, $VBLT, $BLPH, $WINT, $SNDX, $AKAO, $REPH Thanks everyone for your input. I realize my idea is NOT a very good s...

  • Avatar

    $BLPH - LP Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, today announced a poster pr...

  • Avatar

    Frank - As mentioned to earlier, I have a question needing to be answered. I was rereading Dr. KSS' article about $BLPH...

  • Avatar

    Here it is: “Moreover, we expect to communicate the results of our Phase 2 trials for INOpulse therapy to treat sig...

  • Avatar

    $BLPH Doc, From: http://investors.bellerophon.com/phoenix.zhtml?c=253899&p=irol-newsArticle&ID=2220490 “Ou...

  • Avatar

    $BLPH Long: From their Third Quarter 2016 Financial Results report. “Our Phase 2 trials for INOpulse therapy to trea...

  • Avatar

    $BLPH From http://investors.bellerophon.com/phoenix.zhtml?c=253899&p=RssLanding&cat=news&id=2253367 "“Mor...

  • Avatar

    Eyedoc, I'd be interested in your impressions of Aerie Pharmaceuticals ($AERI). They have 2 Phase III trials for gla...

  • Avatar

    $BLPH (long) Just started a position in BLPH at 1.60. Trading extremely well. Phase 2 data (pulmonary hypertension as...

  • Dr. KSS MD PhD

    Buon giorno and happy Ides of February (I know) to all. Someone posted a question overnight that I saw in the small hour...

  • Dr. KSS MD PhD

    Oh absolutely, Cyclosporin is a wonder drug and a horrible agent all at the same time. It saves lives not salvageable by...

  • Dr. KSS MD PhD

    An important new study has appeared in flagship journal Gastroenterology. It confirms strongly a long-held belief among ...

  • Avatar

    Thanks to Doc for bringing up this fascinating topic and for the great discussion following. I am, frankly, flabbergaste...

  • arch1

    Makes me wonder about Tenormin/Atenolol. I do know that street users of ephedrine/amphetamine/meth use bootleg Atenolo...

  • Avatar

    $ITEK no position. The mechanism of action of Trabodenoson in humans as postulaed on the company website is differen...

  • Avatar

    The following current language is from $ITEK's website describing Trabodenoson: "This is a potential new approach to eff...

  • Dr. KSS MD PhD

    Hi...we've only superficially touched on pulmonary hypertension and agents to treat it. PH is a complex field because so...

  • Avatar

    Happy after Thanksgiving to all. I hope the Gummune has recovered from its calorie induced daze. I took a market holiday...

  • arch1

    $GILD news NP; http://www.gilead.com/news/press-releases/2016/9/gilead-terminates-phase-23-study-of-gs5745-in-patient...

  • Avatar

    #NASH $GILD $GNFTF Gilead Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatiti...

  • Dr. KSS MD PhD

    Hi Frank: I have been tracking Eiger closely from its earliest days, as I know one of the VC's who helped start it. Whil...

  • Avatar

    $AUPH Aurinia Pharmaceuticals to Host Lupus Nephritis (LN) Breakfast and Webcast on September 30th in New York. The C...

  • Dr. KSS MD PhD

    I often kvetch here about the sorry state of science. And you may think it's carping, that it's affectational bellyachin...

  • SoGiAm

    Author: JohnM Comment: http://www.stockgumshoe.com/2016/08/ten-common-biotech-investing-mistakes/comment-page-12/#comme...

  • JohnM

    $PTN no position Slingshot Insights upcoming call Bremelanotide Phase 3 Data Is Days Away In Female Sexual Dysfunction...

  • Dr. KSS MD PhD

    Well, this is an interesting find Ben. Sparsentan was being advanced by Retrophin (not to be confused with Recro Pharma)...

  • Dr. KSS MD PhD

    Hi Zimmy: I'm pretty strongly confident in the abilities of the drugs of both Fibrogen and Akebia to really wring out th...

  • arch1

    Ben $KTOV has said it intends to ask to matket it's hypertension drug. Thjat is a crowded field and apparently they hav...

  • Avatar

    Long $RLYP. I am "re-invested" after the surprising FDA "decision" about ZS9 has been published. The paradigm has shif...

  • Anamorph

    Here is a recent medical journal letter from Dr Bakris responding to and refuting an article that seemed to find some fl...

  • Dr. KSS MD PhD

    For anyone reading who has tinnitus, I think it's important not to presume it's an innocent process with no cause and no...

  • Avatar

    Dr. KSS, I don't have an opinion I would feel comfortable offering to you but I found the following on $RETA: Reata ...

  • Avatar

    Hi TWA14; I am not a doctor. I have borderline high blood pressure (around 140 + or - 10). but your's sounds dangerously...

  • SoGiAm

    RLYP long and longest Gummune and Twerpz :-) Merci beaucoup - Ben Biggest near-term lift to $RLYP is ZS-9 PDUFA on May...

  • Dr. KSS MD PhD

    To niizajim: Hi, you were asking the other night about PPI and renal injury. I am really disappointed to hear that your ...

  • LongOnLife

    Thanks for this Dr. KSS. It is pertinent to us older men with low T and the results jive with my experience and gut feel...

  • Avatar

    In my 86th year, I find I am lonesome for all my contemporaries who smoked, since almost without exception they are dead...

  • sogiam

    Quantum Genomics Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission ...

  • Avatar

    $CNAT, $GNFTF Doc you wrote in http://www.stockgumshoe.com/2014/12/microblog-dawn-of-the-planet-of-the-tloglodytes/ ...

  • Avatar

    KITOV http://finance.yahoo.com/news/kitov-pharmaceuticals-pivotal-phase-iii-120000858.html Kitov Pharm (KTOV) drug KIT...

  • Avatar

    Akebia (AKBA) Akebia Announces Presentation of Vadadustat Phase 2 Dialysis Data at American Society of Nephrology K...

  • Avatar

    Just ran across the following published today on RLYP: Tomorrow is the FDA's action date for its review of Relypsa's (R...

  • Avatar

    topical H2O2 for Seb K's was of course patentable. I digress. Minoxidil was used for the Rx of severe hypertension for...

  • sogiam

    GILD- U.S. Food and Drug Administration Approves New Treatment Combination of Gilead’s Letairis® with Tadalafil for P...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch